

Date	Presenter	Title	Journal	Year	Vol	Page
2022/7/5	古本	Teclistamab in Relapsed or Refractory Multiple Myeloma	N Engl J Med	2022	387(18)	1721
	宮崎	骨髄系腫瘍の新しい分類について				
2022/7/12	児嶋	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma	N Engl J Med	2022	386(26)	2482-2494
	長井	A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia	Nat Med	2022	28(6)	1212-1223
2022/7/19	クリクラ学生	INCB84344-201:Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia	Blood Adv	2022	686)	1742-1753
	蓬萊	Molecular international prognostic scoring system for myelodysplastic syndromes	Nejm Evid	2022	1(7)	
2022/7/26	勝岡	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA	Blood	2022	139(6)	835-844
	加藤	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee	Blood	2022	140(11)	1229-1253
2022/9/6	勝岡	第84回日本血液学会 予行				
2022/9/13	西村	第84回日本血液学会 予行				
	古本	第84回日本血液学会 予行				
2022/9/20	松本	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study	Lancet Oncol	2021	22(4)	512-524
	糸永	第84回日本血液学会 予行				
2022/9/27	一瀬	Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus				
	安東	第84回日本血液学会 予行				
2022/10/4	勝岡	第84回日本血液学会 予行	Nat Med	2022	28(10)	2124-2132
	加藤					
2022/10/11	古本	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study	Lancet Oncol	2022	23(8)	1055-1065
	佐藤	TET2-mutant clonal hematopoiesis and risk of gout	Blood	2022	140(10)	1094-1103
2022/10/18	勝岡	第8回日本HTLV-1学会 予行				
2022/10/25		第84回日本血液学会 報告会				
2022/11/1		第84回日本血液学会 報告会				
2022/11/8	児嶋	Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study	Haematologica	2022	107(11)	2675-2684
	蓬萊	Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19	N Engl J Med	2022	386(23)	2188-2200
2022/11/15	西村	Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial	Lancet Haematol	2022	9(9)	e660-e669
	宮崎	Erythroblastic islands foster granulopoiesis in parallel to terminal erythropoiesis	Blood	2022	140(14)	1621-1634
2022/11/22	松本	Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival	Blood	2022	140(18)	1964-1971
	長井	Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma	Nat Med	2022	28(9)	1872-1882
2022/11/29	清水	Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation	J Haematol Oncol	2022	15(1)	126
	坂本	Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial	Clin Infect Dis	2022	75(4)	690-701